Remission of type 2 diabetes mellitus by ileal interposition with sleeve gastrectomy

International Journal of Endocrinology and Metabolism

Volumn 9, Issue 3, 2011, Pages 374-381

  Kota, Sunil Kumar ^a   Ugale, Surendra ^b   Gupta, Neeraj ^b   Naik, Vishwas ^b   Kota, Siva Krishna ^c   Hari Kumar, K V S ^d   Modi, Kirtikumar D ^a  

^a Medwin Hospital   (India)

^b Kirloskar Hospital   (India)

^c Central Security Hospitals   (Saudi Arabia)

^d Department of Laboratory Medicine and Transfusion Medicine   (India)

Author keywords

Diabetes mellitus; Dyslipidemia; Hypertension; Ileal interposition; Sleeve gastrectomy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INTESTINE ANASTOMOSIS; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REMISSION; SLEEVE GASTRECTOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; THERAPY EFFECT; WEIGHT REDUCTION;

EID: 84857286893     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/Kowsar.1726913X.2782     Document Type: Article

References (54)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
2. Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in diabetes care in India: sheer numbers, lack of awareness and inadequate control. J Assoc Physicians India. 2008;56:443-50.
3. Bjork S, Kapur A, King H, Nair J, Ramachandran A. Global policy: aspects of diabetes in India. Health Policy. 2003;66(1):61-72.
4. World Health Organization. Obesity and overweight. [March 2011]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
5. Banting FG, Best CH. The internal secretion of the pancreas. 1922. Indian J Med Res. 2007;125(3):251-66.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607.
7. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27 (Suppl 1):S47-54.
8. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (noninsulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991;34(7):483-7.
9. Gerich JE. Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab. 2000;85(6):2113-5.
10. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucosedependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88(10):4897-903.
11. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol. 1989;257(2 Pt 1):E241-6.
12. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47(3):357-66.
13. Hickey MS, Pories WJ, MacDonald KG, Jr., Cory KA, Dohm GL, Swanson MS, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998;227(5):637-43; discussion 43-4.
14. Greenway SE, Greenway FL, 3rd, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg. 2002;137(10):1109-17.
15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta analysis. JAMA. 2004;292(14):1724-37.
16. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? Diab Vasc Dis Res. 2007;4(2):151-3.
17. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195-7.
18. Kawamura I, Ochiai T. [Current status of obesity surgery as metabolic surgery]. Nihon Geka Gakkai Zasshi. 2006;107(6):305-11.
19. De Paula AL, Macedo A, Prudente A, Silva L, Schraibman V, Neto JG, et al. Neuroendocrine brake for the treatment of morbid obesity: preliminary report. Einstein. 2005;3(2):110-4.
20. Goel R, Amin P, Goel M, Marik S. Early remission of type 2 diabetes mellitus by laparoscopic ileal transposition with sleeve gastrectomy surgery in 23-35 BMI patients. Int J Diabetes Dev Ctries. 2011;31(2):1-6.
21. Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, et al. Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther. 2009;11(12):785-9.
22. DePaula AL, Macedo AL, Rassi N, Machado CA, Schraibman V, Silva LQ, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc. 2008;22(3):706-16.
23. De Paula AL, Stival AR, Macedo A, Ribamar J, Mancini M, Halpern A, et al. Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2). Surg Obes Relat Dis. 2010;6(3):296-304.
24. Tinoco A, El-Kadre L, Aquiar L, Tinoco R, Savassi-Rocha P. Shortterm and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg. 2011;35(10):2238-44.
25. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-50; discussion 50-2.
26. Pons MB. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010;33(Suppl 1):62-9.
27. Eknoyan G. Adolphe Quetelet (1796-1874)-the average man and indices of obesity. Nephrol Dial Transplant. 2008;23(1):47-51.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
29. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992;62(3):249-56.
30. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism. 1979;28(11):1086-96.
31. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89(6):2608-15.
32. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res. 1998;6 (Suppl 2):51S-209S.
33. Bei-Fan Z. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Asia Pac J Clin Nutr. 2002;11 (Suppl 8):S685-93.
34. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr. 2002;11 (Suppl 8):S732-S7.
35. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63.
36. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163-70.
37. Rask E, Olsson T, Soderberg S, Holst Jj J, Tura A, Pacini G, et al. Insulin secretion and incretin hormones after oral glucose in nonobese subjects with impaired glucose tolerance. Metabolism. 2004;53(5):624-31.
38. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31 (Suppl 2):S290-6.
39. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1-11.
40. Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA, et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G795-802.
41. Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control. A review. Physiol Behav. 2008;95(3):271-81.
42. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671-7.
43. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76(2A):4-12.
44. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237(6):751-6; discussion 7-8.
45. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083-6.
46. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
47. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39.
48. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009;32(3):514-20.
49. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35-43.
50. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004-10.
51. Tsuchiya T, Kalogeris TJ, Tso P. Ileal transposition into the upper jejunum affects lipid and bile salt absorption in rats. Am J Physiol. 1996;271(4 Pt 1):G681-91.
52. Pournaras DJ, Jafferbhoy S, Titcomb DR, Humadi S, Edmond JR, Mahon D, et al. Three hundred laparoscopic Roux-en-Y gastric bypasses: managing the learning curve in higher risk patients. Obes Surg. 2010;20(3):290-4.
53. Suter M, Giusti V, Heraief E, Zysset F, Calmes JM. Laparoscopic Roux-en-Y gastric bypass: initial 2-year experience. Surg Endosc. 2003;17(4):603-9.
54. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249-54.